Detailed analysis of a randomized phase III trial: can the tolerability of capecitabine plus docetaxel be improved without compromising its survival advantage?

R Leonard, Joyce O'Shaughnessy, S Vukelja, V Gorbounova, C A Chan-Navarro, Dominique Maraninchi, N Barak-Wigler, Joseph McKendrick, W G Harker, A S Bexton, Chris Twelves

Research output: Contribution to journalArticleResearchpeer-review

50 Citations (Scopus)
Original languageEnglish
Pages (from-to)1379 - 1385
Number of pages7
JournalAnnals of Oncology
Issue number9
Publication statusPublished - 2006

Cite this